Ipamorelin

This is a demonstration store. You can purchase products like this from Versed.

Lyophilized Ipamorelin Powder

Key Features

• Selective GHS‑R1a Agonist: Ipamorelin mimics ghrelin’s GH‑releasing action with minimal off‑target effects on ACTH, cortisol, prolactin, FSH, or LH PubMedWikipedia.

• Optimized Pharmacokinetics: After subcutaneous or intravenous administration, Ipamorelin peaks in plasma GH release within 30–60 min and has a half‑life of ~2 hours, supporting discrete study designs PubMed.

• Dose‑Responsive GH & IGF‑1 Elevation: Demonstrates a clear SC₅₀ of 214 nmol/L and maximal GH production rates (~694 mIU/L/h), with dose‑dependent IGF‑1 increases in humans PubMedSpringer Link.

• High Purity & Stability: Lyophilized powder is typically verified at ≥ 99 % purity by reverse‑phase HPLC, ensuring reproducible assay performance and long shelf‑life PubMed.

• Clean Safety Profile: Clinical studies report Ipamorelin is well‑tolerated at doses up to 0.03 mg/kg twice daily for 7 days, with no significant adverse endocrine changes versus placebo PubMedPubMed.

Applications

• Endocrine Axis Research: Model GH/IGF‑1 feedback loops, pulsatility, and receptor pharmacology in vitro and in vivo systems PubMedSpringer Link.

• Anabolic & Muscle Recovery Studies: Probe GH‑mediated signaling in myoblast differentiation, protein synthesis, and repair pathways ScienceDirect.

• Metabolic Regulation Models: Examine effects on lipolysis, glucose homeostasis, and energy expenditure via GHS‑R1a activation PMC.

• Gastrointestinal Motility Assays: Use as a reference secretagogue in models of gastric emptying and dysmotility, given its action on enteric ghrelin receptors PMC.

• Peptide Kinetics & Formulation: Evaluate delivery systems, half‑life modulation, and degradation pathways in peptide‑drug development PubMedSpringer Link.

Specifications